We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04988386
Recruitment Status : Enrolling by invitation
First Posted : August 3, 2021
Last Update Posted : April 1, 2022
Sponsor:
Information provided by (Responsible Party):
Eidos Therapeutics, a BridgeBio company

Brief Summary:
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)

Condition or disease Intervention/treatment Phase
Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy Drug: Acoramidis (AG10) Phase 3

Detailed Description:

The primary objective of this prospective multi-center, open-label study is to evaluate the long-term safety and tolerability of acoramidis in the context of background heart failure therapy. Selected secondary efficacy endpoints and exploratory pharmacokinetic, pharmacodynamic/biomarker endpoints may also be assessed. All participants who complete 30 months of blinded study treatment and the Month 30 assessments of the double-blind treatment period of the Phase 3 ATTRibute-CM trial (AG10-301) may be eligible to participate in this Open Label Extension (OLE) study of acoramidis. The Day 1 visit in Study AG10-304 may be the same day as the Month 30 visit in Study AG10-301. Under these circumstances, the last dose of Investigational Medicinal Product (IMP) in Study AG10-301 will be the night before the day of the Month 30 visit and the first dose of acoramidis in Study AG10-304 will be during the Study AG10-304 Day 1 visit after baseline assessments have been completed.

Currently, tafamidis is approved for the treatment of ATTR-CM in some regions. Participants are not allowed to be treated with tafamidis or any other ATTR-CM-specific approved or investigational treatments, or therapies used off-label or as non-prescription supplements for ATTR-CM at any time during the study. If participants choose treatment with a prohibited medication, they may be asked to discontinue acoramidis and they may be asked to discontinue/withdraw from the study. Under these circumstances, participants will be asked to complete an early termination visit, and a follow-up visit prior to discontinuation/withdrawal.

Participants are not permitted to participate in another interventional clinical trial (with the exception of Study AG10-301) within 30 days prior to dosing and throughout Study AG10-304. Participants who choose to participate in another interventional clinical trial may be asked to withdraw from acoramidis and/or the study. In such cases, participants will be asked to complete an early termination visit and a follow-up visit. Participation in observational and/or registry studies should be discussed with the Medical Monitor.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 545 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-label study extension study from the AG10-301 double-blind study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Actual Study Start Date : October 27, 2021
Estimated Primary Completion Date : April 15, 2028
Estimated Study Completion Date : May 15, 2028

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AG10
Open-label study all participants will receive AG10 during this study.
Drug: Acoramidis (AG10)
Acoramidis (AG10) twice daily




Primary Outcome Measures :
  1. Incidence of treatment-emergent Adverse Events [Safety and Tolerability] [ Time Frame: 60 months ]
    Incidence of each treatment-emergent adverse events measured over 60 Months or study completion


Secondary Outcome Measures :
  1. Evaluate all-cause mortality and cardiovascular mortality [ Time Frame: 60 months ]
    Assessment of All-cause mortality and CV mortality during study period

  2. Evaluate the effect of acoramidis on the 6-minute walk test (6MWT) [ Time Frame: 60 months ]
    Change from Baseline in distance walked during the 6MWT during study period

  3. Evaluate the effect of acoramidis on health-related quality of life Kansas City Cardiomyopathy Questionnaire [ Time Frame: 60 months ]
    Change from Baseline in Kansas City Cardiomyopathy Questionnaire Overall Score during study period [scale is scored from 0-100, where 0=Poor, 100=Excellent]

  4. Evaluate the effect of acoramidis on the frequency of CV-related hospitalization [ Time Frame: 60 months ]
    assess CV-related hospitalization during the study period



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Completed 30 months of the blinded study treatment in Study AG10-301 and the Study AG10-301 Month 30 visit including assessments and procedures.
  2. Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
  3. Female participants of childbearing potential who engage in heterosexual intercourse must agree to use a highly effective method of contraception beginning with enrollment and continuing for 30 days after the last dose of acoramidis. Female participants using oral contraceptives must agree to use an additional birth control method. While not considered highly effective, a double-barrier method is acceptable. A male participant who is sexually active with a female of childbearing potential and has not had a vasectomy must agree to use a double-barrier method of birth control.

Exclusion Criteria:

  1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Day 1 stroke or transient ischemic attack (TIA) within 90 days prior to Day 1.
  2. Has hemodynamic instability, that in the judgment of the Investigator, would pose too great a risk for participation in the study.
  3. Has had a heart and/or liver transplant or is on the heart transplantation list within the year prior to Day 1
  4. Has had implantation of a cardiac mechanical assist device (CMAD) or is scheduled for implantation of a CMAD
  5. Has confirmed diagnosis of light-chain (AL) amyloidosis at any time during Study AG10-301.
  6. Has estimated glomerular filtration rate (eGFR) by modification of diet for renal disease (MDRD) formula < 15 mL/min/1.73 m2 at Month 27 of Study AG10-301 or at any subsequent central lab value prior to Day 1.
  7. Known hypersensitivity to acoramidis, its metabolites, or formulation excipients.
  8. At the end of Study AG10-301 or at Day 1 of Study AG10-304 (or any time during the study), participant is on prohibited medication.
  9. Females who are pregnant or breastfeeding. A negative urine pregnancy test at the Day 1 visit and at each study visit are required for female participants of childbearing potential.
  10. In the judgment of the Investigator or Medical Monitor, has any clinically important ongoing medical condition or laboratory abnormality or condition that might jeopardize the participant's safety, increase their risk from participation, or interfere with the study.
  11. Participation in another interventional clinical trial (with the exception of Study AG10-301) within 30 days prior to dosing. Participation in observational and/or registry studies should be discussed with the Medical Monitor.
  12. Has any condition that in the opinion of the Investigator or Medical Monitor would preclude compliance with the study protocol such as a history of substance abuse, alcoholism, or a psychiatric condition.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04988386


Locations
Show Show 105 study locations
Sponsors and Collaborators
Eidos Therapeutics, a BridgeBio company
Layout table for additonal information
Responsible Party: Eidos Therapeutics, a BridgeBio company
ClinicalTrials.gov Identifier: NCT04988386    
Other Study ID Numbers: AG10-304
First Posted: August 3, 2021    Key Record Dates
Last Update Posted: April 1, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eidos Therapeutics, a BridgeBio company:
ATTR-CM
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Amyloidosis
Heart Diseases
Cardiovascular Diseases
Proteostasis Deficiencies
Metabolic Diseases